July 30th, 2021
We announce to the medical community that the brand name of PONATIB® (ponatinib) has been changed to NIBCLUS® (ponatinib).
NIBCLUS® (ponatinib) is indicated for the treatment of patients with Chronic Myeloid Leukemia (chronic, accelerated, and blast phases) and acute lymphoblastic leukemia. NIBCLUS® is still commercially available in the same presentations: 60 x 15 mg film-coated tablets and 30 x 45 mg film-coated tablets.
Click here for more product information.
---
NEW NAME, SAME EFFICACY
1 daily dose
Ponatib is now NIBCLUS® Ponatinib
A new horizon In CHRONIC MYELOID LEUKEMIA, chronic, accelerated and blast phases, and ACUTE LYMPHOBLASTIC LEUKEMIA
Same presentations:
- Packs containing 60 film-coated tablets for the 15 mg strength.
- Packs containing 30 film-coated tablets for the 45 mg strength.